•
Dec 31, 2020

Biogen Q4 2020 Earnings Report

Reported a decrease in revenue due to generic entry for TECFIDERA, while making progress in pipeline development and strategic collaborations.

Key Takeaways

Biogen reported Q4 2020 revenue of $2,853 million and GAAP EPS of $2.32. The company is awaiting regulatory decision on aducanumab for Alzheimer's disease and anticipates a financial reset in 2021 due to TECFIDERA generics.

Fourth quarter total revenues were $2,853 million, a 22% decrease versus the prior year.

Fourth quarter GAAP net income and diluted earnings per share (EPS) attributable to Biogen Inc. were $358 million and $2.32, respectively.

Fourth quarter Non-GAAP net income and diluted EPS attributable to Biogen Inc. were $706 million and $4.58, respectively.

Aducanumab for Alzheimer’s disease currently under regulatory review in the U.S., E.U., and Japan with PDUFA date extended to June 7, 2021, in U.S.

Total Revenue
$2.85B
Previous year: $3.67B
-22.3%
EPS
$4.58
Previous year: $8.34
-45.1%
Effective Tax Rate
3.8%
Previous year: 16%
-76.3%
GAAP R&D
$1.73B
Previous year: $692M
+149.4%
GAAP SG&A
$806M
Previous year: $665M
+21.2%
Gross Profit
$2.36B
Previous year: $3.22B
-26.7%
Cash and Equivalents
$1.33B
Previous year: $4.48B
-70.3%
Free Cash Flow
-$453M
Previous year: $1.96B
-123.1%
Total Assets
$24.6B
Previous year: $27.2B
-9.6%

Biogen

Biogen

Biogen Revenue by Segment

Biogen Revenue by Geographic Location

Forward Guidance

Biogen expects full year 2021 revenue to be between $10.45 billion and $10.75 billion, Non-GAAP diluted EPS to be between $17.00 and $18.50, and capital expenditures to be between $375 million and $425 million.

Positive Outlook

  • Assumes aducanumab will be approved in the U.S. by June 7, 2021.
  • Expects an immediate launch of aducanumab with modest revenue in 2021, ramping thereafter.
  • Anticipates utilizing a portion of the remaining share repurchase authorization of $4.6 billion throughout 2021.
  • Expects Non-GAAP R&D expense to be between $2.35 billion and $2.45 billion.
  • Estimates Non-GAAP SG&A expense to be between $2.6 billion and $2.7 billion, including support for the potential launch of aducanumab.

Challenges Ahead

  • Expects a sharp decline of TECFIDERA in the U.S. during the first half of 2021.
  • Anticipates significant erosion of RITUXAN in the U.S.
  • Financial guidance assumes foreign exchange rates as of December 31, 2020, will remain in effect for the year, net of hedging activities.
  • Guidance does not include any impact from potential acquisitions or large business development transactions.
  • Guidance does not include any impact of potential tax or healthcare reform.

Revenue & Expenses

Visualization of income flow from segment revenue to net income